The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).
 
Robert Hsu
Honoraria - DAVA Oncology; The Dedham Group
Consulting or Advisory Role - Takeda; Targeted Oncology
 
Alexis Leyba
No Relationships to Disclose
 
Denaly Chen
No Relationships to Disclose
 
Harris Benjamin Krause
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Wendy Cozen
No Relationships to Disclose
 
Evanthia T. Roussos Torres
Stock and Other Ownership Interests - Synaptical
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca (I); Daiichi Sankyo/Astra Zeneca; Genentech; MorphoSys (I); Seagen (I); Zentalis
Speakers' Bureau - BeiGene (I)
Research Funding - AstraZeneca (Inst)
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Janssen; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Guardant Health; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Puma Biotechnology; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Patrick C. Ma
Honoraria - AstraZeneca; BeiGene
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L
Consulting or Advisory Role - AADi; ANP Technologies; AstraZeneca; Bioatla; Mindmed
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters